血清VEGF和CST4水平对胃肠道癌症患者 T分期的预测价值

Predictive Value of Serum VEGF and CST4 Levels in T Staging of Gastrointestinal Cancer Patients

摘要: 目的：探讨VEGF、CST4水平对胃肠道癌症分期的预测价值，为胃肠道癌症的临床诊治提供新思路。方法：收集安徽医科大学第二附属医院2023年10月~2025年10月的237例胃肠道癌症患者的临床基本信息、实验室指标及病理资料，根据术后病理T分期进行分组，即T1 + T2组、T3 + T4组，使用逐步多因素Logistic回归的方法，确定胃肠道癌症患者T分期的影响因素，受试者工作曲线(ROC)分析VEGF及CST4水平在预测T分期的应用价值。结果：T3 + T4组的淋巴结数量、脉管癌栓及神经侵犯阳性率、CEA、CA724、VEGF、CST4水平显著高于T1 + T2组，进一步的分析表明VEGF、CST4水平、脉管癌栓及神经侵犯是T分期的独立影响因素；ROC曲线显示，VEGF、CST4预测胃肠道癌症T分期的AUC分别为0.656、0.759，均高于其他指标。结论：胃肠道癌症患者的血清VEGF、CST4水平对T分期的预测价值高于传统肿瘤标志物，对于胃肠道癌症的临床分期具有更好的区分能力。

Abstract: Objective: To explore the predictive value of VEGF and CST4 levels on the staging of gastrointestinal cancer, and to provide new ideas for clinical diagnosis and treatment of gastrointestinal cancer. Methods: The clinical basic information, laboratory indexes and pathological data of 237 patients with gastrointestinal cancer in the Second Affiliated Hospital of Anhui Medical University from October 2023 to October 2025 were collected, and they were divided into T1 + T2 group and T3 + T4 group according to postoperative pathological T staging. The influencing factors of T staging of gastrointestinal cancer patients were determined by stepwise multivariate Logistic regression, and the levels of VEGF and CST4 were analyzed by ROC. Results: The number of lymph nodes, the positive rate of vascular tumor thrombus and nerve invasion, the levels of CEA, CA724, VEGF and CST4 in T3 + T4 group were significantly higher than those in T1 + T2 group. Further analysis showed that VEGF, CST4 levels, vascular tumor thrombus and nerve invasion were independent influencing factors for T staging. ROC curve showed that AUC of VEGF and CST4 in predicting T stage of gastrointestinal cancer was 0.656 and 0.759, respectively, which were higher than other indexes. Conclusion: The levels of serum VEGF and CST4 in patients with gastrointestinal cancer have higher predictive value for T staging than traditional tumor markers, and have better differentiation ability for clinical staging of gastrointestinal cancer.